# Title

 Food and Drugs. PART 60â€”PATENT TERM RESTORATION


# ID

 CFR-2018-title21-vol1.Pt. 60


# Structured Analysis Summary

| Type        | Values                                                                                                                                                               |
|:------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'within', 'no later than', 'maximum', 'later than', 'after', 'no less than']                                                                              |
| Duration    | ['30.0 day', '180.0 day', '15.0 day', '6.0 month', '60.0 day', '10 day', '90.0 day']                                                                                 |
| Condition   | ['not subject to', 'unless', 'where', 'subject to', 'when', 'if']                                                                                                    |
| Entities    | ['Time', 'Scope', 'Regulatory', 'U.S. Patent', 'Food', 'United States Patent', 'Rockville, MD', 'Request', 'Patent', 'New', 'Purpose', 'Applicant', 'Filing', 'Act'] |
| Date        | ['1984-10-09']                                                                                                                                                       |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                       |
|:--------------|:------------------------------------------------------------------------------------------------------------------------------|
| before        | product was subject to a regulatory review period before its commercial marketing or use; (2) For human                       |
| after         | for commercial marketing or use of the product after the regulatory review period is the first permitted                      |
| after         | for commercial marketing or use of the product after the regulatory review period is the first permitted                      |
| within        | whether the patent term restoration application was submitted within 60 days after the product was approved for               |
| after         | term restoration application was submitted within 60 days after the product was approved for marketing or use,                |
| within        | whether the patent term restoration application was submitted within 60 days after the product was approved for               |
| after         | of Dockets Management (HFA-305), 5630 Fishers Lane, rm. after                                                                 |
| after         | (iii) Proceedings resulting from objections to the regulation, after commercial marketing has been permitted and later stayed |
| no less than  | and (3) Is conducted over a period of no less than 6 months duration, excluding time required to analyze                      |
| within        | a revision of the regulatory review period determination within 60 days after its initial publication in the                  |
| after         | the regulatory review period determination within 60 days after  its initial publication in the Federal Register.             |
| within        | revision, the applicant shall respond to the request within  15 days.                                                         |
| within        | determine the regulatory review period for a product within 30 days of the receipt of a written                               |
| no later than | Any person may file a petition with FDA, no later than 180 days after the publication of a regulatory                         |
| after         | petition with FDA, no later than 180 days after the publication of a regulatory review period determination                   |
| no later than | with FDA a written response to the petition no later than 30 days after the applicant's receipt of a                          |
| after         | to the petition no later than 30 days after the applicant's receipt of a copy of the                                          |
| within        | with due diligence during the regulatory review period. within                                                                |
| after         | (a) Within 90 days  after FDA receives a petition filed under &#167;&#8201;60.30(a), the                                      |
| maximum       | were granted, the petition would not affect the maximum  patent extension the applicant sought in the application.            |
| later than    | (a) Any person may request, not  later than 60 days after the publication under &#167;&#8201;60.34(a) of                      |
| after         | person may request, not later than 60 days after the publication under &#167;&#8201;60.34(a) of FDA's due diligence           |
| within        | state whether the requesting party seeks a hearing within 30 days or 60 days of FDA's receipt                                 |
| before        | Ten days  before the hearing, FDA will notify the requesting party,                                                           |
| after         | Within 30 days  after the completion of the due diligence hearing, the                                                        |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 60.0 day   | (ii) Is the first permitted commercial marketing or use of the product for administration to a food-producing animal, whichever is applicable, under the provision of law under which the regulatory review period occurred;                                                                                                                                                                                               |
|            |               (4) Informing the U.S. Patent and Trademark Office whether the patent term restoration application was submitted within 60 days after the product was approved for marketing or use, or, if the product is an animal drug approved for use in a food-producing animal, verifying whether the application was filed within 60 days of the first approval for marketing or use in a food-producing animal; and |
|            |               (5) Providing the U.S. Patent and Trademark Office with any other information relevant to the U.S. Patent and Trademark Office's determination of whether a patent related to a product is eligible for patent term restoration.                                                                                                                                                                             |
| 60.0 day   | (ii) Is the first permitted commercial marketing or use of the product for administration to a food-producing animal, whichever is applicable, under the provision of law under which the regulatory review period occurred;                                                                                                                                                                                               |
|            |               (4) Informing the U.S. Patent and Trademark Office whether the patent term restoration application was submitted within 60 days after the product was approved for marketing or use, or, if the product is an animal drug approved for use in a food-producing animal, verifying whether the application was filed within 60 days of the first approval for marketing or use in a food-producing animal; and |
|            |               (5) Providing the U.S. Patent and Trademark Office with any other information relevant to the U.S. Patent and Trademark Office's determination of whether a patent related to a product is eligible for patent term restoration.                                                                                                                                                                             |
| 6.0 month  | (e) For purposes of this section, a &#8220;major health or environmental effects test&#8221; may be any test which:                                                                                                                                                                                                                                                                                                        |
|            |               (1) Is reasonably related to the evaluation of the product's health or environmental effects, or both:                                                                                                                                                                                                                                                                                                       |
|            |               (2) Produces data necessary for marketing approval; and                                                                                                                                                                                                                                                                                                                                                      |
|            |               (3) Is conducted over a period of no less than 6 months duration, excluding time required to analyze or evaluate test results.                                                                                                                                                                                                                                                                               |
| 60.0 day   | (a) Any person may request a revision of the regulatory review period determination within 60 days after its initial publication in the Federal Register.                                                                                                                                                                                                                                                                  |
| 15.0 day   | (b) Unless the applicant is the person requesting the revision, the applicant shall respond to the request within 15 days.                                                                                                                                                                                                                                                                                                 |
| 180.0 day  | (a) FDA will consider a regulatory review period determination to be final upon expiration of the 180-day period for filing a due diligence petition under &#167;&#8201;60.30 unless FDA receives:                                                                                                                                                                                                                         |
|            |               (1) New information from PTO records, FDA records, or FDA centers that affects the regulatory review period determination;                                                                                                                                                                                                                                                                                   |
|            |               (2) A request under &#167;&#8201;60.24 for revision of the regulatory review period determination;                                                                                                                                                                                                                                                                                                           |
|            |               (3) A due diligence petition filed under &#167;&#8201;60.30; or                                                                                                                                                                                                                                                                                                                                              |
|            |               (4) A request for a hearing filed under &#167;&#8201;60.40.                                                                                                                                                                                                                                                                                                                                                  |
| 180.0 day  | (b) FDA will notify PTO that the regulatory review period determination is final upon:                                                                                                                                                                                                                                                                                                                                     |
|            |               (1) The expiration of the 180-day period for filing a due diligence petition; or                                                                                                                                                                                                                                                                                                                             |
|            |               (2) If FDA has received a request for a revision, a due diligence petition, or a request for a hearing, upon resolution of the request for a revision, the petition, or the hearing, whichever is later.                                                                                                                                                                                                     |
| 30.0 day   | (a) FDA will determine the regulatory review period for a product within 30 days of the receipt of a written request from PTO for such a determination and a copy of the patent term restoration application.                                                                                                                                                                                                              |
| 30.0 day   | (b) FDA may extend the 30-day period if:                                                                                                                                                                                                                                                                                                                                                                                   |
| 180.0 day  | (a) Any person may file a petition with FDA, no later than 180 days after the publication of a regulatory review period determination under &#167;&#8201;60.20, that challenges FDA's determination by alleging that the applicant for patent term restoration did not act with due diligence in seeking FDA approval of the product during the regulatory review period.                                                  |
| 30.0 day   | (a) The applicant shall file with FDA a written response to the petition no later than 30 days after the applicant's receipt of a copy of the petition.                                                                                                                                                                                                                                                                    |
| 90.0 day   | (a) Within 90 days after FDA receives a petition filed under &#167;&#8201;60.30(a), the agency will either deny the petition under paragraph (b) or (c) of this section or investigate and determine under &#167;&#8201;60.36 whether the applicant acted with due diligence during the regulatory review period.                                                                                                          |
| 60.0 day   | (a) Any person may request, not later than 60 days after the publication under &#167;&#8201;60.34(a) of FDA's due diligence determination, that FDA conduct an informal hearing on the due diligence determination.                                                                                                                                                                                                        |
| 30.0 day   | (c) The request shall state whether the requesting party seeks a hearing within 30 days or 60 days of FDA's receipt of the request.                                                                                                                                                                                                                                                                                        |
| 60.0 day   | (c) The request shall state whether the requesting party seeks a hearing within 30 days or 60 days of FDA's receipt of the request.                                                                                                                                                                                                                                                                                        |
| 10 day     | Ten days before the hearing, FDA will notify the requesting party, the applicant, and the petitioner, orally or in writing, of the date, time, and location of the hearing.                                                                                                                                                                                                                                                |
| 30.0 day   | Within 30 days after the completion of the due diligence hearing, the Commissioner will affirm or revise the determination made under &#167;&#8201;60.34(a) and will publish the due diligence redetermination in the Federal Register, notify PTO of the redetermination, and send copies of the notice to PTO and to the requesting party, the applicant, and the petitioner.                                            |


## Condition

| Condition      | Context                                                                                                                 |
|:---------------|:------------------------------------------------------------------------------------------------------------------------|
| subject to     | to medical devices, food additives, or color additives subject to regulation under the Federal Food, Drug, and Cosmetic |
| if             | and Drug Administration findings on due diligence challenges. if                                                        |
| unless         | Regulations are to chapter I of title 21, unless  otherwise noted.                                                      |
| when           | in 35 U.S.C. 156 apply to those terms when  used in this part.                                                          |
| subject to     | one or more subjects and that is either subject to requirements for prior submission to the Food and                    |
| not subject to | Federal Food, Drug, and Cosmetic Act, or is not subject to the requirements for prior submission to FDA under           |
| subject to     | The term does not include experiments that are  subject to the provisions of part 58 regarding nonclinical laboratory   |
| subject to     | section 201(t) of the Act and which is subject to  premarketing approval under section 721 of the Act.                  |
| subject to     | section 201(s) of the Act and which is subject to  premarketing approval under section 409 of the Act.                  |
| subject to     | section 201(h) of the Act and which is subject to  premarketing approval under section 515 of the Act.                  |
| subject to     | as follows: (1) Verifying whether the product was subject to a regulatory review period before its commercial marketing |
| when           | (ii) Under the process claimed in the patent when the patent claims a method of manufacturing the                       |
| if             | product was approved for marketing or use, or, if the product is an animal drug approved for                            |
| where          | and the dates used in calculating each phase. where                                                                     |
| if             | is required, the effective date of the exemption. if                                                                    |
| if             | the Act is required, the IRB approval date. if                                                                          |
| if             | FDA to secure premarket approval of the device. if                                                                      |
| unless         | shall respond to the request within 15 days. unless                                                                     |
| unless         | for filing a due diligence petition under &#167;&#8201;60.30 unless FDA receives: (1) New information from PTO records, |
| if             | (b) FDA will not if y PTO that the regulatory review period determination                                               |
| if             | and shall set forth sufficient facts, including dates if possible, to merit an investigation by FDA of                  |
| if             | restoration application, due diligence petition, and FDA records. if                                                    |
| if             | did not exercise due diligence such that, even if the petition were granted, the petition would not                     |


## Entities

| Entities             | Context                                                                                                                         |
|:---------------------|:--------------------------------------------------------------------------------------------------------------------------------|
| Food                 | Food  and Drugs.                                                                                                                |
| Scope                | Scope .                                                                                                                         |
| Patent               | Patent term restoration is available for certain patents related                                                                |
| Food                 | Food and Drug Administration actions in this area include:                                                                      |
| United States Patent | actions in this area include: (1) Assisting the United States Patent and Trademark Office in determining eligibility for patent |
| Purpose              | Purpose .                                                                                                                       |
| United States Patent | are intended to complement those promulgated by the United States Patent and Trademark Office to implement those parts of       |
| Act                  | drug products submitted under section 505(b) of the Act  or section 351 of the Public Health Service                            |
| Act                  | drug products submitted under section 505(b) of the Act  or section 351 of the Public Health Service                            |
| United States Patent | (15) PTO means the  United States Patent  and Trademark Office.                                                                 |
| U.S. Patent          | (a) Upon written request from the  U.S. Patent  and Trademark Office, FDA will assist the                                       |
| U.S. Patent          | (a) Upon written request from the  U.S. Patent  and Trademark Office, FDA will assist the                                       |
| U.S. Patent          | the regulatory review period occurred; (4) Informing the U.S. Patent and Trademark Office whether the patent term restoration   |
| U.S. Patent          | the regulatory review period occurred; (4) Informing the U.S. Patent and Trademark Office whether the patent term restoration   |
| U.S. Patent          | the regulatory review period occurred; (4) Informing the U.S. Patent and Trademark Office whether the patent term restoration   |
| U.S. Patent          | (b) FDA will notify the  U.S. Patent and Trademark Office of its findings in writing,                                           |
| Rockville, MD        | 1061,  Rockville, MD  20852.                                                                                                    |
| Rockville, MD        | 1061,  Rockville, MD  20852.                                                                                                    |
| Regulatory           | Regulatory  review period determinations.                                                                                       |
| Rockville, MD        | 1061,  Rockville, MD  20852.                                                                                                    |
| New                  | diligence petition under &#167;&#8201;60.30 unless FDA receives: (1) New information from PTO records, FDA records, or FDA      |
| Rockville, MD        | 1061,  Rockville, MD  20852.                                                                                                    |
| Time                 | Time  frame for determining regulatory review periods.                                                                          |
| Filing               | Filing , format, and content of petitions.                                                                                      |
| Applicant            | Applicant  response to petition.                                                                                                |
| Request              | Request  for hearing.                                                                                                           |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                         |
|:-----------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1984-10-09 | The application shall contain information relevant to the determination of the regulatory review period as stated in the &#8220;Guidelines for Extension of Patent Term Under 35 U.S.C. 156&#8221; published on October 9, 1984, in PTO's Official Gazette and as required by 37 CFR chapter I. |


